All publications

Unveiling the Potential of Labrasol® ALF Labrafac™ MC60 and Capryol® 90 as Permeation Enhancers to Address Low Bioavailability Issues

  • Whitepaper

American Pharmaceutical Review - Oct 2024

Cécile Morin, Philippe Caisse

In vitro, ex vivo, and in vivo tests show that Labrasol® ALF, Labrafac™ MC60, and Capryol® 90 are effective and safe permeation enhancers. They work by temporarily opening tight junctions in the intestinal lining, potentially improving the bioavailability of poorly permeable drugs, including small molecules (BCS III and IV) and large molecules like peptides and proteins.

The Role of Lipids in Mitigation of Food Effect

  • Whitepaper

American Pharmaceutical Review - Mar 2024

Inayet Ellis, Masumi Dave

In this paper, after a general description of the effect of food on gastrointestinal physiology, drugs, and formulation, the role of lipids is explained along with their digestion and absorption mechanisms. Case studies with self-emulsifying drug delivery systems (SEDDS) are presented as a way to mitigate the food effect. Current in vitro methods to determine indicators for the food effect during the drug development stage are also described.

An All-Purpose Vehicle for Low-Energy Capsule Filling

  • Whitepaper

Tablets&Capsules - Apr 2023

Jasmine Musakhanian; Masumi Dave; Elise Dauphin-Chanard

Capsules are perceived as elegant, easy-to-swallow dosage forms, widely used for delivery of nutraceutical and medicinal preparations. Advances in capsule technologies have hugely facilitated the incorporation of liquid, semi-solid, and solid ingredients into capsules. 

LIPID-BASED EXCIPIENTS – Misconceptions About Lipid-Based Drug Delivery

  • Whitepaper

Drug Development & Delivery - Apr 2023

Rollie Fuller and Ron Permutt

Cannabinoid molecules and their love of lipid excipients

  • Whitepaper

Pharmaceuticals & Cosmetic Review - Feb 2022

Gattefossé

Formulation forum – A Quick Approach for Evaluation of Drug-Excipient Compatibility: Case of Acetylsalicylic Acid

  • Whitepaper

Drug Development & Delivery - 2021

Dr. Masumi Dave, Rollie Fuller

In this study, the authors monitor acetylsalicylic acid (ASA) hydrolysis in different formulations using UPLC and TAM with the objective of comparing these methods for agreement, speed, and efficiency in predicting drug stability. In parallel, we assess the impact of the excipient choices on the stability of the ASA.

Solid lipid nanocarrier development toolbox for increasing oral bioavailability of API

  • Whitepaper

American Pharma Review, May-June 2020 issue, pp 69-75 - May 2020

Camille Dumont

In this comprehensive article, the author describes the latest tools available to develop solid lipid nanoparticles: how to prepare and characterize solid lipid nanoparticles, how to evaluate encapsulation efficiency and intestinal permebility.

DOs and DON’Ts for developing successful SEDDS formulations to enhance API bioavailability

  • Whitepaper

Tablets&Capsules, p.37-39  - Apr 2020

Inayet Ellis

A snapshot of lipid excipients for topical formulations

  • Whitepaper

Pharma Times – Vol. 51 – No. 59 - Sep 2019

Gattefossé

Lipid excipients in pharmaceutical technologies
Nabil FARAH and Joel DENIS

Lipidic excipients in drug delivery for solubility and bioavailability enhancement
Prashantkumar K. PARMAR, Srilaxmi G. RAO, Arvind KK. BANSAL

From exploration of lipids to its exploitation in market: Pharmaceuticals, Nutraceuticals and Herbal
Saurabh ARORA, Abhinav GARG, Karishma KAPOOR

A snapshot of lipid excipients for topical formulations
Renuka TIWARI, Ketkee DESHMUKH, Agnivesh SHRIVASTAVA, Kanchan KOHLI

Strategic lipid-based delivery interventions for enhancing oral bioavailability of BCS II/IV drugs
Teenu SHARMA, Ranjot KAUR, Sumant SAINI, Atul JAIN, Bhupinder SINGH

 Unleashing role of excipients in overcoming formulation challenges
Meenakshi VENKATARAMAN, Megha MARWAH, Mangal NAGARSENKER

Role of lipid excipients in oral sustained release drug delivery systems
Divya JAIN, Namita DESAI